Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
NeoBe Therapeutics develops engineered live biotherapeutics for oncology, combining synthetic biology and immunology to create next-generation cell therapies. The company serves cancer patients through collaborations with leading academic institutions and investors.
2 investors
2 investors
Neopathology develops tissue diagnostic assays and a proprietary platform called ONEPATHOLOGY that delivers rapid, accurate disease diagnosis and patient stratification for precision medicine treatments. The company combines spatial biology and deep-tissue profiling technologies to standardize tissue diagnostics.
2 investors
NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
2 investors
NΔRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.
2 investors
Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.
2 investors
Neuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.
2 investors
Neuraura Biotech develops proprietary 3D micro-electrode and microsensor technology for high-fidelity neural recording and percutaneous stimulation, used to improve diagnostic and therapeutic solutions for neurological, psychiatric and sensory conditions. The company commercializes technology transferred from the University of Calgary, with a stated focus on chronic, underserved health conditions including women's health.
2 investors
Neuraworx Medical Technologies is a medical device company developing Intelligent Cerebrovascular Pacing, a bioelectronic technology intended to enhance the brain's glymphatic system function and cerebral fluid clearance. The technology targets brain health by improving removal of extracellular biomolecular debris associated with aging and disease.
2 investors
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy. It also maintains a proprietary drug delivery and stabilization technology portfolio applicable to proteins, peptides, and small and large molecules.
2 investors
2 investors
2 investors
Shanghai NewMed Medical is a Chinese medical device company founded in 2015 that develops, manufactures, and sells transcatheter artificial heart valves and interventional ventricular assist systems. Its products target interventional treatment of cardiovascular disease for clinicians and patients in China.
2 investors
New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.
2 investors
NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
2 investors
NexMR, an ETH Zurich spin-off, develops light-coupled NMR hardware, consumables, and automated analysis software to increase throughput and reduce resource use in NMR-based drug discovery pipelines. Its sensitivity-enhanced technology targets early-stage drug discovery workflows, including hit affinity determination and screening of challenging targets.
2 investors
Next Life Sciences works in reproductive healthcare, focused on solutions for couples.
2 investors
Nextmol (Bytelab Solutions SL) is a computational chemistry company that develops molecular modeling and AI tools, offered both as services and via a SaaS platform, to accelerate the design of more sustainable chemicals for the chemical industry. A spin-off of the Barcelona Supercomputing Center, its work focuses on generative AI for molecular design, property prediction, and chemical space exploration for applications such as polymers and surfactants.
2 investors
NFlection is a biopharmaceutical company developing novel therapeutics. The page does not state what the company's specific products or therapeutic focus are.
2 investors
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway. Its current programs target hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia, both in Phase 2 clinical trials.
2 investors
2 investors
Nibec is a South Korean biotech company that develops peptide-based therapeutics and dental biomaterials, including bone graft materials, periodontal tissue regeneration products, tooth-whitening agents, and drug-delivery platforms. It supplies materials to global implant and pharmaceutical companies and pursues clinical development of treatments for conditions such as pulmonary fibrosis and inflammatory bowel disease.
2 investors
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.
2 investors
NKA Bio develops antibody-based medicines for critically ill and trauma patients to extend survival time during medical emergencies. The company's lead candidate, NKA01, is an anti-shock toxin antibody administered by emergency medical services to stabilize trauma patients and buy time for transport and surgical intervention.
2 investors